Document Detail


Fusidic acid viscous eyedrops--an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists.
MedLine Citation:
PMID:  16792734     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent changes in UK law have allowed UK-based optometrists to sell and supply fusidic acid viscous eyedrops, providing it is in the course of their professional activity and in an emergency. Alternatively, the optometrist may access fusidic acid viscous eyedrops, for a named patient, using a written order supplied to a pharmacy. This review provides details of the legal background to these changes, examines the common causes of a bacterial conjunctivitis, examines the mechanism of action of this narrow spectrum antibiotic as a bacteriostatic agent, reviews the susceptibility of common ocular isolates of bacteria to the drug and presents details of the expected pharmacokinetics of the viscous eyedrops. From this perspective, a systematic review is provided of the clinical studies which have investigated the use of fusidic acid viscous eyedrops and their outcome. The indicated use is generally for the treatment of bacterial conjunctivitis and/or blepharoconjunctivitis, especially that caused by Staphylococcus, but not Streptococcus or Haemophilus sp. (more likely associated with concurrent nasopharyngeal infections). The usual regimen for use is twice daily for 5-10 days, depending on severity, and can initially be used more intensively (four times per day). It may also be used for the management of corneal and conjunctival abrasions and foreign body injuries, or some cases of chronic blepharitis.
Authors:
Michael J Doughty; Gordon N Dutton
Related Documents :
21168114 - Perceptions of complementary therapies among swedish registered professions in surgical...
15177844 - Antibiotic resistance in the institutionalized elderly.
15035764 - Nosocomial pneumonia in the intensive care unit: controversies and dilemmas.
18166664 - Using focus groups to revise an educational booklet for people living with methicillin-...
11994824 - The duration and degree of end-of-life dependency of home care clients and hospital inp...
24133944 - Nice guidance points the way to tackling eczema in children.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)     Volume:  26     ISSN:  0275-5408     ISO Abbreviation:  Ophthalmic Physiol Opt     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-23     Completed Date:  2006-12-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8208839     Medline TA:  Ophthalmic Physiol Opt     Country:  England    
Other Details:
Languages:  eng     Pagination:  343-61     Citation Subset:  IM    
Affiliation:
Department of Vision Sciences, Glasgow Caledonian University, Glasgow, UK. m.doughty@gcal.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Animals
Anti-Bacterial Agents / administration & dosage*,  pharmacokinetics,  pharmacology
Conjunctivitis, Bacterial / drug therapy
Fusidic Acid / administration & dosage*,  pharmacokinetics,  pharmacology
Great Britain
Humans
Microbial Sensitivity Tests
Ophthalmic Solutions / therapeutic use*
Optometry / legislation & jurisprudence*
Practice Guidelines as Topic
Protein Synthesis Inhibitors / administration & dosage,  pharmacokinetics,  pharmacology
Rabbits
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Ophthalmic Solutions; 0/Protein Synthesis Inhibitors; 6990-06-3/Fusidic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Specificity of the monoclonal antibody 3H8 in the immunohistochemical identification of Candida spec...
Next Document:  Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance.